



Exhibiting EXPO 2025  
Osaka Kansai

Company Name: Pharma Foods International Co., Ltd.  
Representative: Representative Director, Mujo Kim  
Stock Exchange Market: Tokyo Prime (2929)  
Head Office: 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto 615-8245  
Contact Number: +81-75-394-8600

News Release

September 24, 2025

## **“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ~Driving Future Growth through Strategic License Agreement~**

Pharma Foods International Co., Ltd. (Head Office: Kyoto, Japan; Representative Director: Mujo Kim; hereinafter “the Company”) announces the completion of a Phase I single dose clinical study (Registry Identifier: jRCT2031240187) of “MT-3534” by Mitsubishi Tanabe Pharma Corporation (hereinafter: “Mitsubishi Tanabe Pharma”), in July 2025.

MT-3534 is an antibody therapeutic drug candidate, co-discovered with Mitsubishi Tanabe Pharma through the Company’s proprietary antibody discovery platform, ALAgene® technology.

This clinical milestone marks a transformative advance for the Company, accelerating progress toward market entry and enhancing the potential for substantial revenue generation. It further solidifies the Company’s leadership and long-term growth trajectory in innovative antibody therapeutics.

The Company is dedicated to developing innovative therapeutics targeting intractable diseases such as autoimmune disorders, cancers, and inflammatory diseases, where traditional mammalian antibody diseases methods have historically faced limitations. This clinical milestone highlights the robustness and utility of the Company’s proprietary ALAgene® technology platform. The Company will strategically and steadily expand its pipeline, strengthen its innovation capabilities and drive future growth.

The Company’s proprietary ALAgene® technology platform enables the creation of humanized therapeutic antibodies from chickens against disease-causing targets that are challenging to address in mamalian systems. This platform provides a powerful and versatile approach for developing next-generation antibody therapeutics.

For further inquiries, please contact:

Corporate Strategy Department, Public Relations Group

E-mail: [press@pharmafoods.co.jp](mailto:press@pharmafoods.co.jp)